Combination of Adoptive Immunotherapy with Herceptin for Patients with HER2-expressing Breast Cancer

Anticancer Research

Volumn 23, Issue 6 A, 2003, Pages 4443-4449

  Kubo, Makoto ^a   Morisaki, Takashi ^a   Kuroki, Hideo ^a   Tasaki, Akira ^a   Yamanaka, Naoki ^a   Matsumoto, Kotaro ^a   Nakamura, Katsuya ^a   Onishi, Hideya ^a   Baba, Eishi ^a   Katano, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Activated lymphocytes; Antibody dependent cellular cytotoxicity (ADCC); Fc RIII; HER2; Herceptin; Trastuzumab

Indexed keywords

CHROMIUM 51; INTERLEUKIN 2; OKT 3; PICIBANIL; RECOMBINANT COLONY STIMULATING FACTOR; TRASTUZUMAB;

ADOPTIVE IMMUNOTHERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG BINDING; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; EFFECTOR CELL; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LYMPHOCYTE ACTIVATION; MESOTHELIUM CELL; ONCOGENE NEU; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TARGET CELL; TUMOR CELL;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, FC;

EID: 0344872749     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235: 177-182, 1987.
2. Slamon DJ, Gololphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Press MF: Studies of the HER2/neu proto-oncogene in human breast ovarian cancer. Science 244: 707-712, 1989.
3. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, McKenzie S, Yin S and Bast Jr. RC: Overexpression of HER2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087-4091, 1990.
4. McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, Tobin BMJ and Carney DN: Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 51: 3296-3303, 1991.
5. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Sö derborgh J, Anbazhagan R, Styles J, Rudenstam C.-M., Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Kürki K, Castiglione M, Collins J, Lindtner J and Senn HJ: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10: 1049-1056, 1992.
6. HER2 monoclonal antibody in patients with HER2/neuoverexpressing metastatic breast cancer. J Clin Oncol 14: 737-744, 1996.
7. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ and Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726, 2002.
8. Osoba D and Burchmore M: Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin). Semin Oncol 26: 84-88, 1999.
9. Stebbing J, Copson E and O'Reilly S: Herceptin (trastuzumab) in advanced breast cancer. Cancer Treat Rev 26: 287-290, 2000.
10. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastic breast cancer that overexpresses HER2. N Eng J Med 344: 783-792, 2001.
11. Bell R: Duration of therapy in metastatic breast cancer: management using Herceptin®. Anti-cancer Drugs 12: 561-568, 2001.
12. Shak S, for the Herceptin Multinational Investigator Study Group: Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Semin Oncol 26: 60-77, 1999.
13. Lenferink AEG, Busse D, Flanagan WM, Yakes FM and Arteaga CL: ErbB2/neu kinase modulates cellular p27Kip1 and cyclin D1 through multiple signaling pathways. Cancer Res 61: 6583-6591, 2001.
14. Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H and Matsumoto Y: Impaired antibody-dependent cellular cytotoxicity mediated by Herceptin in patients with gastric cancer. Cancer Res 62: 5813-5817, 2002.
15. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM and Fox JA: Nonclinical studies addressing the mechanism of action of trasuzumab (Herceptin). Semin Oncol 26: 60-70, 1999.
16. Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, Dennis PA and Lipkowitz S: Down-regulation of the erbB-2 receptor by trastuzumab (Herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61: 4892-4900, 2001.
17. Münster PN, Marchion DC, Basso AD and Rosen N: Degdradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-Akt-dependent pathway. Cancer Res 62: 3132-3137, 2002.
18. HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285-4289, 1992.
19. HER2 monoclonal antibodies. Cancer Immunol Immunother 37: 255-263, 1993.
20. Bonavida B, Katz J and Hoshino T: Mechanism of NK activation by OK-432 (Streptococcus pyogenes). Cell Immunol 102: 126-35, 1986.
21. Uchida A and Klein E: Activation of human blood lymphocytes and monocytes by the streptococcal preparation OK-432: enhanced generation of soluble cytotoxic factors. Immunol Lett 10: 177-81, 1985.
22. Sato T, Midorikawa Y, Yamashita T, Araki A and Sendo F: The neutrophil as an information transmitter in tumor inhibition by a streptococcal biological response modifier, OK-432. Cancer Immunol Immunother 43: 77-86, 1996.
23. Katano M and Torisu M: Neutrophil-mediated tumor cell destruction in cancer ascites. Cancer 50: 62-68, 1982.
24. Saito M, Nanjo M and Kataoka M: Adoptive immunotherapy by pantropic killer cells recovered from OK-432-induced tumor sites in mice. Cancer Res 48: 4163-4167, 1988.
25. Kawano Y, Watanabe M, Kubota T, Nishibori H, Kurihara N, Teramoto T and Kitajima M: A streptococcal preparation (OK-432) enhances monoclonal antibody NCC-ST-421 cytotoxicity against human colon cancer. Anticancer Res 17: 2449-2454, 1997.
26. Gochi A, Orita K, Fuchimoto S, Tanaka N and Ogawa N: The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients. Br J Cancer 84: 443-451, 2001.
27. Nio Y, Nagami H, Tamura K, Tsubono M, Nio M, Sato M, Kawabata K, Hayashi H, Shiraishi T, Imai S, Tsuchitani T, Mizuta J, Nakagawa M and Fukumoto M: Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion. Br J Cancer 80: 775-785, 1999.
28. Uchida A and Hoshino T: Clinical studies on cell-mediated immunity in patients with malignant disease. Cancer 45: 476-483, 1980
29. Torisu M, Katano M, Kimura Y, Itoh H and Takesue M: New approach to management of malignancy ascites with a streptococcal preparation, OK-432. Improvement of host immunity and prolongation of survival. Surgery 93: 357-364, 1983.
30. Jacobs TW, Gown AM, Yaziji H, Barnes MJ and Schnitt SJ: Specificity of HercepTest in determing HER-2/neu status of breast cancers using the United States Food and Drug Administration-Approved Scoring System. J Clin Oncol 17: 1983-1987, 1999.
31. International Union Against Cancer: TNM Classification of Malignant Tumor, 5th edn. Springer, New York, 1997.
32. Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, Baselga J and Caligiuri MA: Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 31: 3016-3025, 2001.
33. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F and Slamon D: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: 2241-2251, 1999.
34. Clynes RA, Towers TL, Presta LG and Ravetch JV: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6: 443-446, 2000.